- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03420677
Enhancement of Sleep With Wearables (WESA)
March 2, 2021 updated by: Swiss Federal Institute of Technology
Enhancement of Sleep Slow Wave Activity Using Wearable Auditory Stimulation Devices and Its Consequences on Daytime Functioning: a Randomized, Counter-balanced Crossover Study
Sleep, specifically deep sleep, plays a central role in healthy brain function, cardio-vascular processes, mood and quality of life.
Auditory stimulation during one night of sleep has previously been shown to improve deep sleep and along with memory formation in both young and older adults.
Yet, it remains unclear whether long-term auditory stimulation considerably improves sleep quality over longer time periods and how it affects daytime functioning such as cognition, mood, quality of life and peripheral functions (e.g.
cardio-vascular).
Due to the importance of deep sleep for brain and body and the presence of many conditions that involve reduced deep sleep (e.g.
ageing) assessing the beneficial impact of long-term sleep enhancement and its consequences is of central interest.This study will assess the effect of auditory stimulation over two weeks (interleaved with a two weeks washout period) in a cohort of healthy young and older adults using portable recording and stimulation devices.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
33
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Zurich
-
Zürich, Zurich, Switzerland, 8092
- Swiss Federal Institute of Technology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 84 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Informed Consent as documented by signature
- For women: Hormonal contraception, if menstrual cycle is still present or has been present less than a year ago
- Good general health status
- Stable home situation (e.g. long-term place to live) that allows for reliable application of intervention for the duration of the study
- Male and Female subjects 18-35 years of age or 60-84 years of age
- German speaking
Exclusion Criteria:
- Women who are pregnant or breast feeding,
- Known or suspected non-compliance, drug or alcohol abuse,
- Intake of sleep altering medication
- Inability to follow the procedures of the study, e.g. due to language problems, cognitive deficits
- Participation in another study with investigational drug within the 30 days preceding and during the present study,
- Presence or history of diagnosed psychiatric/neurologic disorder/lesion of the central nervous system (CNS),
- Diagnosed internal disease,
- Presence of sleep disorders,
- Shift-work (work during the night) or situations that require several awakenings during the night (e.g. newborn)
- Travelling more than 2 time zones in the last month before intervention starts or during intervention (study start will be shifted accordingly)
- Hearing disability/ hearing aid
- Skin disorders/problems in face region that will worsen with /not allow adhesive electrode application
- Nicotine/Cannabis use
- High caffeine consumption (> 5 servings/day; including coffee, energy drink)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Application of tones
During non-rapid eye movement (NREM) sleep short tones will be played
|
During NREM sleep, tones (max.
60 dB) will be played using a portable, safe, in-home device.
This device records biosignals (e.g.
brain activity) and precisely times the tones during NREM sleep.
It was developed and produced by the ETH Zurich and approved for use in this study by Swissmedic
|
Sham Comparator: No application of tones
During NREM sleep no short tones will be played
|
This is the sham-control intervention; The device will only record biosignals but will not play tones.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sleep quality
Time Frame: From baseline period to study completion, assessed up to 2 months
|
Objective information about sleep macro- and microstructure will be assessed including measures like sleep architecture, amount of slow wave activity (SWA), amount of spindles, awakenings during sleep, and sleep fragmentation.
In addition, subjective sleep quality will be obtained by questionnaires every morning over the intervention period.
These measures will show whether auditory stimulation enhanced overall sleep quality compared to sham.
|
From baseline period to study completion, assessed up to 2 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Daily functioning - Mood
Time Frame: From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
Mood will be digitally assessed using a daily mood scale over the intervention period
|
From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
Daily functioning - Quality of life
Time Frame: From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
Quality of life will be assessed using a World Health Organization (WHO) quality of life assessment before and after each intervention period
|
From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
Daily functioning - Vigilance
Time Frame: From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
Vigilance will be assessed using a digital psychomotor vigilance task, assessed daily over the intervention period
|
From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
Daily functioning - Cognition
Time Frame: From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
Cognition will be assessed using a digital test battery before and after each intervention
|
From the beginning of the first intervention period until the end of the second intervention period, assessed within a time period up to 6 weeks
|
Physiological parameters - Cardiovascular
Time Frame: From baseline period to study completion, assessed up to 2 months
|
R-R interval based assessments will be obtained using wearable monitors
|
From baseline period to study completion, assessed up to 2 months
|
Physiological parameters - Physical activity
Time Frame: Through study completion, approximately 2 months
|
Physical activity levels will be obtained using wearable monitors
|
Through study completion, approximately 2 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Device usability
Time Frame: From the first home visit until the end of the second intervention period, assessed within a time period up to 2 months
|
Questionnaires will be used to track specific information about the portable intervention device including information about its usability, discomfort and blinding to the condition
|
From the first home visit until the end of the second intervention period, assessed within a time period up to 2 months
|
Diary
Time Frame: Through study completion, approximately 2 months
|
Information about daily habits will be digitally assessed
|
Through study completion, approximately 2 months
|
Incidence of Intervention-related Adverse Events [Safety and Tolerability]
Time Frame: Through study completion, approximately 2 months
|
Any adverse or serious adverse events during the study period will be assessed
|
Through study completion, approximately 2 months
|
Chronotype
Time Frame: Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Assessment of circadian type
|
Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Handedness
Time Frame: Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Assessment of handedness
|
Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Menstrual cycle
Time Frame: Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Assessment of menstrual cycle information in woman
|
Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Height
Time Frame: Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Assessment of height
|
Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Hip-to-waist ratio
Time Frame: Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Assessment of hip and waist circumference
|
Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Blood pressure
Time Frame: Through study completion, approximately 2 months
|
Assessment of blood pressure
|
Through study completion, approximately 2 months
|
Weight
Time Frame: Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Assessment of weight
|
Before start of intervention period (single-time assessment during one initial 1-day visit)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 7, 2018
Primary Completion (Actual)
March 5, 2019
Study Completion (Actual)
October 30, 2020
Study Registration Dates
First Submitted
December 4, 2017
First Submitted That Met QC Criteria
January 26, 2018
First Posted (Actual)
February 5, 2018
Study Record Updates
Last Update Posted (Actual)
March 3, 2021
Last Update Submitted That Met QC Criteria
March 2, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Other Study ID Numbers
- WESA_2017-01436
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep
-
University of Wisconsin, MadisonPhilips HealthcareCompletedSleep, Slow-wave Sleep, Sleep Enhancement, Sleep Optimization
-
Brain Electrophysiology Laboratory CompanyRecruiting
-
University GhentEuropean CommissionEnrolling by invitation
-
Northumbria UniversityCompletedSleep | Mood | Poor Quality Sleep | Good Sleep HabitUnited Kingdom
-
Baylor College of MedicineEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruiting
-
Brain Electrophysiology Laboratory CompanyCompletedSleep | Sleep HygieneUnited States
-
Koko Home, Inc.Stanford UniversityRecruitingSleep Disorder | Insomnia | Sleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Sleep HygieneUnited States
-
Medical College of WisconsinChildren's Hospital and Health System Foundation, Wisconsin; Divine Savior...Active, not recruitingSleep | Sleep HygieneUnited States
-
Aretaieion University HospitalRecruitingSleep Disorder | Sleep Initiation and Maintenance Disorders | Sleep | Sleep Disturbance | Surgery | Anesthesia | Sleep Fragmentation | Sleep Disorders, Circadian RhythmGreece
-
Brigham and Women's HospitalCharite University, Berlin, Germany; Stanford UniversityRecruitingSleep Disorders, Intrinsic | Sleep Wake Disorders | Sleep Disorders, Circadian Rhythm | Advanced Sleep Phase Syndrome (ASPS) | Delayed Sleep Phase Syndrome | Shift-Work Sleep Disorder | Delayed Sleep Phase | Non-24 Hour Sleep-Wake Disorder | Advanced Sleep Phase Syndrome | Advanced Sleep Phase | Irregular... and other conditionsUnited States
Clinical Trials on Application of tones
-
University Children's Hospital, ZurichActive, not recruiting
-
MicroTransponder Inc.National Institute on Deafness and Other Communication Disorders (NIDCD)Completed
-
Dow University of Health SciencesRecruiting
-
University Hospital, MontpellierCompleted
-
Milton S. Hershey Medical CenterChildren's Miracle NetworkCompletedVery Low Birth Weight InfantsUnited States
-
Medical University of GrazAbbott Diagnostics DivisionCompletedContrast Media Induced Nephropathy (CIN)Austria
-
Bayero University Kano, NigeriaCompleted
-
American British Cowdray Medical CenterUnknown
-
SerenaGroup, Inc.Musculoskeletal Transplant FoundationUnknownVenous Leg UlcersUnited States
-
University Hospital, Clermont-FerrandRecruitingOral MucositisFrance